CYCLAFEM 7/7/7 Drug Patent Profile

Which patents cover Cyclafem 7/7/7, and when can generic versions of Cyclafem 7/7/7 launch?

Cyclafem 7/7/7 is a drug marketed by Ph Health and is included in one NDA.

The generic ingredient in CYCLAFEM 7/7/7 is ethinyl estradiol; norethindrone. There is one drug master file entry for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norethindrone profile page.

Summary for CYCLAFEM 7/7/7

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	6
Patent Applications:	219
DailyMed Link:	CYCLAFEM 7/7/7 at DailyMed

US Patents and Regulatory Information for CYCLAFEM 7/7/7

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ph Health	CYCLAFEM 7/7/7	ethinyl estradiol; norethindrone	TABLET;ORAL-28	076338-001	Nov 16, 2010		DISCN	No	No

Last updated: April 29, 2026

CYCLAFEM 7/7/7: Market Dynamics and Financial Trajectory

CYCLAFEM 7/7/7 is a combined oral contraceptive marketed as a cyclic 28-day regimen. The commercial trajectory is shaped by three forces: (1) fixed demand anchored to contraception prevalence and payer formularies, (2) price pressure from generics and therapeutic alternatives, and (3) channel concentration in retail pharmacy distribution in markets where branded lifecycle management and manufacturer rebate intensity determine net pricing.

Because CYCLAFEM 7/7/7 is a branded product name tied to a specific dosing schedule, the market outcome depends on the country-specific brand authorization, labeling (estrogen/progestin composition), and local competitive set. Without those jurisdictional identifiers and corresponding financial reporting, market size, revenue, margins, and category share cannot be stated from first principles.

What is the competitive set that drives CYCLAFEM 7/7/7 uptake?

The competitive set is standard for combined oral contraceptives:

• Same-class fixed-dose combinations (other 21/7 and 24/4 cyclic regimens, and 28-day regimens depending on label)
• Therapeutic substitutes: transdermal patch and vaginal ring where reimbursed and where switching is clinically and administratively easy
• Generic brands of the same active ingredients and strength where patent protection has expired

Market dynamics in this class are dominated by:

• Formulary placement: tiering and preferred status determine prescribing volume and pharmacy fill behavior
• Net price erosion: branded products face discounting and rebates as payers rationalize formularies around lower net cost
• Switchability: patients can switch between brands within the same hormonal class, subject to counseling and adherence

How does the dosing schedule affect switching and persistence?

A 28-day “7/7/7” pattern typically maps to cyclic exposure with hormone-free intervals or reduced exposure days depending on the exact label composition. In practice, schedule design influences:

• Adherence and persistence: patients who prefer fewer perceived “break days” or predictable cycles may show higher persistence
• Prescriber preference: some clinicians prefer regimens with reduced bleeding or improved cycle control claims, where supported by labeling and evidence
• Pharmacy substitution: if the product is considered therapeutically equivalent under local pharmacy substitution rules, substitution can reduce branded share even when prescriptions specify the brand

Clinical persistence matters because contraception demand is recurring. Lower persistence accelerates churn to alternatives and increases the value of “preferred” net pricing at the pharmacy counter.

What drives net pricing in combined oral contraceptives?

Net pricing for branded contraceptives is usually a function of payer leverage and competitive substitution. Key levers:

• Rebates and administrative fees: manufacturers trade rebates for preferred formulary status
• Patient cost sharing: copay cards or patient assistance can be used where allowed, but payer restrictions and therapeutic substitution cap the effect
• Segment mix: markets with higher private insurance penetration and retail pharmacy utilization can sustain stronger branded net pricing than markets dominated by public formularies

For CYCLAFEM 7/7/7, the financial trajectory is therefore less about differentiation on chemistry and more about the brand’s position in the local reimbursement algorithm and the extent of generic penetration.

How does generic competition typically impact revenue for a branded COC?

In the combined oral contraceptive market, generic entry compresses:

• Wholesale and list prices quickly
• Brand unit growth versus category totals
• Gross margin as branded prices converge toward net cost

The net impact depends on:

• Whether generics are identical in formulation and dosing schedule
• Whether the branded product has a label distinction that payers accept as clinically relevant (for example, cycle control outcomes that affect adherence)
• The intensity of manufacturer contracting and pharmacy channel management

What financial trajectory should be expected given typical branded lifecycle behavior?

A branded COC typically shows one of two trajectories: 1) Late-life stabilization: unit share holds despite price pressure if the brand retains preferred formulary access and patient/physician preference 2) Decline acceleration: share erodes as generics expand, copay requirements increase, and prescriptions become substitutes at the pharmacy counter

CYCLAFEM 7/7/7’s likely financial path under generic pressure is a decline in net price with either:

• a slower decline in units (if still preferred), or
• a faster decline in units (if considered substitute and if rebates are insufficient to maintain tier status)

What market-level KPIs track CYCLAFEM 7/7/7 performance?

For decision-grade monitoring, the relevant KPIs are:

• Category and segment share: combined oral contraceptive share by units
• Brand share at retail: prescription fill share (not just script volume)
• Net price index: measured against generic benchmarks in the same strength range
• Persistence rate: continuation within 3, 6, and 12 months after initiation (or a comparable local metric)
• Formulary tier status changes: movements between preferred and non-preferred tiers and their timing

These KPIs determine whether a branded product survives price erosion by holding unit share or fails when both price and volume compress.

What does regulatory and product labeling typically change for market access?

Regulatory updates can shift market access through:

• Switching rules and pharmacy substitution policies influenced by active ingredient equivalence and product labeling
• Reimbursement coding tied to dosing schedule
• Physician comfort and patient counseling requirements that influence initiation rates

For CYCLAFEM 7/7/7, any label-specific differences that justify non-substitution would be the primary protection against volume loss. Absent such differentiation, the product is treated as replaceable within the class.

What does the financial outcome depend on beyond “drug performance”?

In this category, “drug performance” is mostly a function of adherence and tolerability, which is similar across equivalent combinations. Financial outcomes depend more on:

• Contracting: net pricing achieved through payer and pharmacy contracting
• Channel strategy: whether the manufacturer maintains inventory visibility and ordering incentives
• Competitive timing: how quickly generics and competing brands expand after loss of exclusivity or after formulary review cycles
• Patient access programs: where allowed and enforceable, these can partially offset copay-driven switching

Can specific revenue, margin, or growth numbers be provided for CYCLAFEM 7/7/7?

No. CYCLAFEM 7/7/7-specific revenue, profit, market share, or growth figures are not determinable from the provided prompt, because:

• the product’s jurisdictional listing, active ingredient composition, and authorization status are not specified, and
• financial reporting for branded contraceptives is typically aggregated at company or portfolio level, not disclosed per named regimen, in most markets.

The correct investment and R&D framing is to model financial trajectory using category structure (generic penetration, formulary tiering, and substitution rules) and to tie the product to a specific active ingredient and market authorization profile. Without that linkage, any numerical projection would be unsupported.

---

Key Takeaways

• CYCLAFEM 7/7/7’s market dynamics follow combined oral contraceptive norms: demand is anchored, but branded profitability is driven by payer placement and resistance to substitution.
• The financial trajectory is shaped by net pricing erosion from generic competition and by unit-share retention or loss depending on formulary tiering and pharmacy substitution enforcement.
• Track unit share at retail, net price index versus generics, persistence/continuation, and formulary tier movement to predict profit trajectory.
• CYCLAFEM 7/7/7-specific revenue and margin figures cannot be stated from the prompt without jurisdiction-linked product identity and financial disclosure sources.

---

FAQs

1) What is the main driver of branded revenue in combined oral contraceptives?
Formulary placement and net price achieved through rebates and pharmacy contracting, which determine prescription fills and branded unit share.

2) Why do generics hit branded oral contraceptives quickly?
Therapeutic equivalence and substitution rules let pharmacists switch prescriptions to lower net-cost options, reducing both price and volume.

3) What KPI best predicts whether a COC brand will stabilize financially?
Retail fill share and persistence/continuation rates, which reflect adherence and ongoing demand under payer cost pressure.

4) Does the dosing schedule materially change competitive outcomes?
It can affect adherence and cycle control preferences, but in most markets it does not prevent substitution unless labeling supports non-substitution and payers treat it as distinct.

5) What operational levers usually extend a brand’s life in this category?
Contracting to retain preferred tier status, patient access programs where permitted, and channel incentives that reduce switching at the pharmacy counter.

---

References (APA)

[1] U.S. Food and Drug Administration. (n.d.). Combined oral contraceptives (COCs): information for patients and healthcare professionals. https://www.fda.gov/